Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey
详细信息 查看全文
- 作者：K. Kawaguchi (12)
H. Ishiguro (3) hishimd@kuhp.kyoto-u.ac.jp
S. Morita (4)
S. Nakamura (5)
S. Ohno (6)
N. Masuda (7)
H. Iwata (8)
K. Aogi (9)
K. Kuroi (10)
M. Toi (1)
Japan Breast Cancer Research Group (JBCRG) - 关键词：CYP3A4 – ; Docetaxel – ; Drug exposure – ; Facial erythema – ; Hand ; foot syndrome – ; H2 blocker
- 刊名：Breast Cancer Research and Treatment
- 出版年：2011
- 出版时间：November 2011
- 年：2011
- 卷：130
- 期：2
- 页码：627-634
- 全文大小：1.6 MB
- 参考文献：1. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24(31):4963–4970. doi:
2. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178–1184. doi:
3. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15(9):3149–3155
4. Suh Y, Chun CC, Oh S, Song B, Jung S (2008) Comparison of one-day premedication for TAC chemotherapy with three-day regimen for node-positive breast cancer patients. J Clin Oncol 26: 15s. Abstr 621
5. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68(4):356–366. doi:
6. Ishiguro H, Yano I, Toi M (2009) Important drug interactions for clinical oncologists. In: Caldwell GW, Atta-ur-Rahman YanZ, Choudhary MI et al (eds) Frontiers in drug design and discovery, vol 4. Bentham Science Publishers, Dubai, pp 97–121
7. Murray LS, Jodrell DI, Morrison JG, Cook A, Kerr DJ, Whiting B, Kaye SB, Cassidy J (1998) The effect of cimetidine on the pharmacokinetics of epirubicin in patients with advanced breast cancer: preliminary evidence of a potentially common drug interaction. Clin Oncol (R Coll Radiol) 10(1):35–38
8. Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF (1984) The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol 18(3):421–430
9. Koch M, Dezi A, Ferrario F, Capurso I (1996) Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 156(20):2321–2332
10. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823
11. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Anton A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27(11):1753–1760. doi:
12. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56(6):1296–1302
13. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99–114
14. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75(5):448–454. doi:
15. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54(10):1271–1294
16. Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38(13):1677–1684
17. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187–196
18. Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23(19):4424–4429. doi:
19. Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73(7):333–346
20. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R (2002) Docetaxel-induced nail changes–a neurogenic mechanism: a case report. J Neurooncol 58(2):167–174
21. Mukohara T, Takeda K, Miyazaki M, Takifuji N, Terakawa K, Negoro S (2001) Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48(5):356–360
22. Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16(10):3426–3432
23. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263–1268
24. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI (1996) Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334(22):1435–1439
25. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815–832. doi:
26. de Jonge ME, Huitema AD, van Dam SM, Rodenhuis S, Beijnen JH (2005) Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Ther Drug Monit 27(6):756–765
27. Buzdar AU, Cuzick J (2006) Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res 12(3 Pt 2):1037s–1048s. doi:
28. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758–1764 - 作者单位：1. Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan2. Department of Surgery, Osaka Red Cross Hospital, Osaka, Japan3. Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto, 606-8507 Japan4. Department of Biostatistics and Epidemiology, Yokohama City University Medical Center, Yokohama, Japan5. Breast Center, Showa University Hospital, Tokyo, Japan6. Division of Breast Oncology, National Kyushu Cancer Center, Fukuoka, Japan7. Department of Surgery, Breast Oncology, Osaka National Hospital, Osaka, Japan8. Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan9. Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan10. Department of Surgery, Division of Clinical Trials and Research, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology - 出版者：Springer Netherlands
- ISSN：1573-7217
文摘
Steroids and H2 blockers are commonly used as supportive care for taxane-containing chemotherapy, but they also affect docetaxel’s primary metabolizer, cytochrome P450 3A4. This retrospective observational study was performed to better understand the effects of these compounds on docetaxel-induced skin toxicities, specifically hand-foot syndrome (HFS) and facial erythema (FE), a relationship that is currently poorly understood. Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer. We obtained data for 993 patients from 20 institutions. Twenty percent received H2 blockers, and all patients received dexamethasone. Univariate and multivariate analyses revealed that H2 blockers are associated with a significantly higher incidence of both HFS and FE. The incidence of FE was significantly higher for the docetaxel + cyclophosphamide (TC) regimen than for non-TC regimens combined. Dexamethasone usage did not affect the incidence of either HFS or FE. In conclusion, use of H2 blockers as premedication in breast cancer patients receiving docetaxel significantly increases the risk of both HFS and FE.